C91.02 Acute lymphoblastic leukemia, in relapse

Name of the Condition

• Acute lymphoblastic leukemia, in relapse
• ICD-10 Code: C91.02

Summary

Acute lymphoblastic leukemia (ALL) in relapse is a recurrence of the disease after a period of remission, where leukemic cells reappear and resume uncontrolled proliferation. This condition indicates that the initial treatment was effective temporarily but did not eliminate all leukemic cells, allowing the disease to return. Relapse can occur in the bone marrow, blood, or other organs, and requires prompt intervention to manage disease progression.

Causes

The causes of ALL in relapse stem from residual leukemic cells that survived initial therapy, often due to inherent resistance or incomplete eradication. Genetic mutations in lymphoid precursor cells that drive the disease may persist or evolve, contributing to recurrence. Environmental exposures, genetic predispositions, or prior treatments (e.g., chemotherapy) may have influenced the initial development and subsequent relapse.

Risk Factors

• Prior incomplete response to initial ALL treatment
• High-risk genetic features of the leukemia
• Short duration of remission (e.g., less than 12-18 months)
• Presence of minimal residual disease after treatment
• Certain cytogenetic abnormalities (e.g., Philadelphia chromosome-positive ALL)
• Weakened immune system from prior therapies

Symptoms

• Fatigue and weakness
• Fever or night sweats
• Unexplained weight loss
• Frequent infections
• Easy bruising or bleeding
• Swollen lymph nodes, liver, or spleen
• Bone or joint pain
• Recurrence of prior ALL symptoms

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to detect abnormal lymphocyte counts and bone marrow aspiration/biopsy to identify leukemic cells. Additional tests, such as flow cytometry or genetic analysis, may confirm relapse and assess disease burden. Imaging (e.g., CT scans) evaluates organ involvement, while lumbar puncture checks for central nervous system relapse.

Treatment Options

Treatment focuses on re-inducing remission, often with intensified chemotherapy regimens, targeted therapies (e.g., tyrosine kinase inhibitors for Philadelphia chromosome-positive ALL), or immunotherapy (e.g., CAR-T cells). Stem cell transplantation may be considered for eligible patients. Supportive care (e.g., blood transfusions, infection prevention) manages symptoms and complications.

Prognosis and Follow-Up

Prognosis depends on factors like age, time to relapse, and response to re-treatment. Early relapse (within 12 months) or resistant disease may have a poorer outlook. Follow-up includes regular blood tests, bone marrow assessments, and imaging to monitor for further recurrence. Long-term surveillance addresses late effects of therapy.

Complications

• Severe infections due to low white blood cell counts
• Bleeding or anemia from reduced platelet/red blood cell production
• Organ damage (e.g., liver, spleen) from leukemic infiltration
• Treatment-related toxicities (e.g., organ dysfunction, secondary cancers)
• Central nervous system involvement or relapse

Lifestyle & Prevention

• Maintain a balanced diet to support immune function
• Practice good hygiene to reduce infection risk
• Avoid exposure to known carcinogens (e.g., benzene)
• Follow prescribed treatment and monitoring schedules
• Manage stress through supportive care or counseling

When to Seek Professional Help

Seek immediate medical attention for:

• Persistent or worsening fatigue, fever, or bleeding
• Unexplained weight loss or night sweats
• New or recurrent swollen lymph nodes, organ enlargement, or bone pain
• Signs of infection (e.g., chills, cough, or urinary symptoms)

Tips for Medical Coders

Document the timing and nature of relapse (e.g., bone marrow, extramedullary) and any prior treatment history. Ensure coding aligns with clinical confirmation of relapse, as this impacts resource utilization and care planning. Note that C91.02 is specific to relapsed ALL and should not be used for initial diagnosis or remission states.